Celgene Cellular Therapeutics Announces Clinical Transplant of Human Placenta-Derived Stem Cells
Celgene Cellular Therapeutics (CCT), a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced the clinical application of a human placenta-derived stem cells (HPDSCs) for hematopoietic reconstitution. The groundbreaking transplant occurred at the LSU Health Sciences Center Children’s Hospital (LSU) on March 28, 2008 to treat a pediatric patient with Acute Lymphoblastic Leukemia (ALL), a cancer of the bone marrow and blood. Following the birth of the patient’s sibling in December 2007, HPDSCs, along with cord blood, were collected and cryo-preserved and both products were used in the transplant.
CCT owns proprietary technologies for collecting, processing, and storing HPDSCs. HPDSCs are immature and versatile stem cells with potentially broad therapeutic applications in, for example, leukemia and other hematological malignancies, solid tumor cancers, and autoimmune diseases
. CCT is also conducting research on other types of stem cells derived from the placenta that are obtained via additional proprietary methodologies.